Efficacy & Safety of Oral Ivermectin and Topical Permethrin in the Treatment of Scabies

Akhter M1, Bhuiyan I2, Hossain MS3, Khan ZH4, Akhter M5, Mumtaz F6

Abstract:

Background: Scabies is one of the most common skin diseases in our country. It is caused by the mite Sarcoptes scabiei var hominis, which is an ecto-parasite infesting the epidermis. Scabies is highly contagious. Prevalence is high in congested or densely populated areas. Individuals with close contact with an affected person should be treated with scabicidal which is available in both oral and topical formulations. The only oral but highly effective scabicidal known to date is Ivermectin. Amongst topical preparations, Permethrin 5% cream is the treatment of choice.

Objective: To evaluate the efficacy & safety of oral Ivermectin compared to topical Permethrin in the treatment of scabies.

Methodology: This prospective, non-randomized study was conducted at the out-patient department of Dermatology and Venereology of Shaheed Suhrawardy Medical College & Hospital over a period of 6 months, from August 2016 to January 2017. The study population consisted of one hundred patients having scabies, enrolled according to inclusion criteria. They were divided into two groups. Group A was subjected to oral Ivermectin and the Group B to Permethrin 5% cream. Patient were followed up on day 7, 14 and assessed for the efficacy and safety.

Result: The mean scoring with SD in Group A and Group B were 8.26 ± 2.22 and 7.59 ± 2.01 respectively at the time of observation. The difference between the mean score of the two group is not significant (p=0.117) The mean scoring with SD in group A and group B were 4.54 ± 2.05 and 1.64 ± 1.84 respectively at 7th days. The difference between the mean score of the two group is significant (p<0.001). The mean scoring with SD in group A and group B were 2.68± 2.35 and .36± 1.10 respectively at 14th day difference between the mean score of the group is significant (p<0.001).

Conclusion: Topical application of Permethrin 5% cream is more effective and safer than oral Ivermectin in the treatment of scabies.

Key Words: Ivermectin, permethrin, scabies

Conflict of Interest: None
Received: 21.03.2019
Accepted: 27.08.2019
www.banglajol.info/index.php/JSSMC

Introduction:

Human infestation by Sarcoptes scabiei var hominis, an obligate human ecto-parasite causes scabies. Scabies affects all races and social classes worldwide, but accurate figures of its prevalence are difficult to obtain. Incidence of scabies is quite high in India, Bangladesh and Pakistan. In Bangladesh, out of total population having skin diseases, 80% of are suffering from scabies.1 In a community based cross-sectional study, scabies was found in the second position among the infectious skin diseases in a rural area of Bangladesh.2

Scabies is usually transmitted by close physical contact, such as prolonged hand-holding or sharing of bed.3 Itching is usually the most obvious manifestation of scabies. It is generally worst at night and when the patient is warm.
The onset occurs 3–4 weeks after the infection is acquired, and coincides with a widespread eruption of inflammatory papules. The pathognomonic lesions of scabies are burrows. Burrows occur on the wrists, borders of hands, sides of fingers and the finger web spaces, feet, particularly the instep and, in males, on the genitalia. They are often present on the palms and soles of young children and the elderly. 

There have been many suggested remedies for scabies including topical sulphar, 5% permethrin, benzyl benzoate, malathion, lindane, crotamiton, Monosulfiram and topical and systemic Ivermectin. The choice of therapy is determined not only by efficacy and potential toxicity, but also by considerations such as cost, ease of application, presence of secondary eczematization and age of the patient.

Permethrin 5% cream is an effective scabicide. At present, it is the topical treatment of choice. Permethrin is a synthetic derivative of the insecticide pyrethrum and function as a neurotoxin to mites and has low toxicity to human.

The only oral but highly effective scabicide known to date is Ivermectin. A single dose of 200 ug/kg body weights will be effective in many cases of ordinary scabies. Higher cure rates are obtained with two doses separated by an interval of a week. It is effective, inexpensive and easy to administer.

Materials and Methods

The study was conducted on 100 patients having scabies at the out-patient department of Dermatology and Venereology at Shaheed Suhrawardy Medical College Hospital, Dhaka during a period of 6 months, from August 2016 to January 2017, out of which 50 patients were treated with topical Permethrin and 50 patients with oral Ivermectin.

A purposive sampling was carried out. All the patients were diagnosed clinically and allocated into two random groups, Group A and Group B. All the patients had given informed written consent.

Pregnant and lactating women, patients with immunodeficiency or severe systemic disease, with heavily crusted or nodular lesions, secondary infection or eczematization, coexisting dermatological disease and with known hypersensitivity to the trial drugs were excluded from the study.

A total of 100 patients with scabies were enrolled in the study. They were randomized into two groups. Group A Ivermectin (n=50) and Group B Permethrin (n=50). All patients completed 2 weeks study period were reviewed after 7th day and 14th day.

Outcome measures were assessed at baseline and at 7th day and 14th day interval.

Results and Observation:

The mean scoring with SD in Group A and Group B were 8.26 ± 2.22 and 7.59 ± 2.01 respectively at the time of observation. The difference between the mean score of the two group is not significant (p=0.117) The mean scoring with SD in group A and group B were 4.54 ± 2.05 and 1.64 ± 1.84 respectively at 7th days. The difference between the mean score of the two group is significant (p<0.001). The mean scoring with SD in group A and group B were 2.68± 2.35 and .36± 1.10 respectively at 14th day difference between the mean score of the group is significant (p<0.001).

Table-I

Distribution of patients according to sex:

<table>
<thead>
<tr>
<th>Sex</th>
<th>Group-A Ivermectin (n=50)</th>
<th>Group-B Permethrin (n=50)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%)</td>
<td>No. (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>27 (54.0)</td>
<td>26 (52.0)</td>
<td>0.841ns</td>
</tr>
<tr>
<td>Female</td>
<td>23 (46.0)</td>
<td>24 (48.0)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>50 (100.0)</td>
<td>50 (100.0)</td>
<td></td>
</tr>
</tbody>
</table>

Chi-square test was done to measure the level of significance, ns= not significant. Figure within parentheses indicated in percentage

Table-II

Distribution of patients according to age group

<table>
<thead>
<tr>
<th>Age (in years)</th>
<th>Group-A Ivermectin (n=50)</th>
<th>Group-B Permethrin (n=50)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%)</td>
<td>No. (%)</td>
<td></td>
</tr>
<tr>
<td>13 – 22</td>
<td>06 (12.0)</td>
<td>12 (24.0)</td>
<td></td>
</tr>
<tr>
<td>23 – 32</td>
<td>13 (26.0)</td>
<td>14 (28.0)</td>
<td></td>
</tr>
<tr>
<td>33 – 42</td>
<td>15 (30.0)</td>
<td>11 (22.0)</td>
<td></td>
</tr>
<tr>
<td>43 – 52</td>
<td>10 (20.0)</td>
<td>08 (16.0)</td>
<td></td>
</tr>
<tr>
<td>&gt;52</td>
<td>06 (12.0)</td>
<td>05 (10.0)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>50 (100.0)</td>
<td>50 (100.0)</td>
<td></td>
</tr>
</tbody>
</table>

Mean ± SD 37.86±12.81 34.28±12.74 0.156ns
Table II

<table>
<thead>
<tr>
<th>Distribution of patients according to site of involvement.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site of involvement</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td>Finger webs</td>
</tr>
<tr>
<td>Wrist</td>
</tr>
<tr>
<td>Periumbilical region</td>
</tr>
<tr>
<td>Genitalias</td>
</tr>
<tr>
<td>Areola</td>
</tr>
<tr>
<td>Axillae</td>
</tr>
</tbody>
</table>

*Chi-square test was done to measure the level of significance

Table IV

<table>
<thead>
<tr>
<th>Distribution of patients according to clinical findings of integumentary system.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical findings of integumentary system</td>
</tr>
<tr>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>Erythematous papules</td>
</tr>
<tr>
<td>Excoriation</td>
</tr>
<tr>
<td>Burrow</td>
</tr>
<tr>
<td>Nocturnal pruritus</td>
</tr>
</tbody>
</table>

Table V

<table>
<thead>
<tr>
<th>Efficacy of Ivermectin &amp; Permethrin at 1st &amp; 2nd week (n=100) after treatment according to scoring.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>Base line</td>
</tr>
<tr>
<td>7th Days</td>
</tr>
<tr>
<td>14th Days</td>
</tr>
</tbody>
</table>

Table 5 shows the distribution of patients according to scoring. The mean scoring with SD in group A and group B were 8.26 ± 2.22 and 7.59 ± 2.01 respectively at the time of observation. The difference between the mean score of the two group is not significant (p=0.117) The mean scoring with SD in group A and group B were 4.54 ± 2.05 and 1.64 ± 1.84 respectively at 7th days. The difference between the mean score of the two group is significant (p<0.001). The mean scoring with SD in group A and group B were 2.68±2.35 and 3.6±1.10 respectively at 14th day difference between the mean score of the group is significant (p<0.001).

Table VI

<table>
<thead>
<tr>
<th>Adverse Effects of Ivermectin &amp; Permethrin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse effect</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Nausea</td>
</tr>
<tr>
<td>Vomiting</td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>Pruritis</td>
</tr>
<tr>
<td>Burning</td>
</tr>
</tbody>
</table>

Discussion:
Scabies is one of the most common infectious diseases in our country. In this study, we evaluated the efficacy & safety of oral Ivermectin and topical Permethrin in the treatment of scabies. Hundred patients diagnosed of scabies on history and examination was recruited as per inclusion criteria. They were divided by using random number table into group A and group B. Oral Ivermectin were given to group A in a single dose of 200µg/kg body weight. Group B were given single application of topical Permethrin 5% cream at night on whole body for 12 hours. Patients were followed up on day 7, 14 and assessed for the efficacy and safety. In the present study male patients were predominant than female in group A and B. In group Amale was 27 (56.7%) and female was 23 (43.3%) cases respectively. In group B male was 26 (53.3%) and female was 24 (46.7%) cases respectively. The difference between these two group was not statistically significant (p=0.795). Similar results were found in a study that overall males are more affected by scabies than females.

According to age majority of the patients were in both groups were from 13-22 to 33-42 years in this study. The
difference between the age group was not statistically significant (P = 0.156). In general, prevalence of scabies is more in children & young adult but it can affect all ages. In the study shows that the most common site was the wrist and genitalias 48 (96.0%) followed by peri-umbilical region 47 (94.0%), finger web 45 (90.0%) lower on axillae 35 (70.0%) and areola 23 (46.0%). In group B shows that the most common site was genitalias 49 (98.0%) followed by finger web 47 (94.0%), wrist 46 (92.0%), peri-umbilical region 45 (90.0%), axillae 33 (66.0%) and areola 24 (48.0%). The differences among the site of involvement of two groups were not significant. Almost similar results were found in a study that the most common site was the genitalia (98%) followed by wrist (96%) then peri-umbilical region (94%), and web space (94%) lower on axilla (70%) and areola (48%).

Nocturnal pruritus was the most common clinical findings of integumentary system followed by erythematous papules, excoriations and burrows. There is no significant difference between the two groups in clinical features. The cure rate was more in case of single application of topical Permethrin than single oral Ivermectin at 1st week, which was significant (p =< 0.001). At 2nd week topical Permethrin has more cure rate than oral Ivermectin & it was also significant (p =< 0.001). According to Aisha Mushtaq et al. topical Permethrin is used nowadays for being safer and more effective than the previously used other drugs.

The scoring of follow up and observation shows that the outcome of patients with topical Permethrin was better than the oral Ivermectin. Some previous study documented that single oral Ivermectin provide a cure rate of 70% whereas topical Permethrin was associated with 98.0% cure rate at 2nd week of treatment. According to Reena Sharma, Archana Singal, both Permethrin and Ivermectin in both single and two dose regimen are equally efficacious and well tolerated in scabies. Usha and Nair have shown efficacy of Ivermectin 200µg/kg to be equivalent to topical 5% Permethrin. According to Munazza S, Lamees MM, M Jahangir. A Comparison of efficacy of single topical permethrin and single oral ivermectin in the treatment of scabies. J Pak Assoc Dermatol 2012; 22:45-49.

In the present study there was no clinically significant difference in nature, frequency, of severity of adverse events between the two treatment groups, as reported in earlier studies.

Conclusion
In conclusion, our study demonstrated that administration of single application of topical Permethrin was an effective and safe treatment for the treatment of scabies. Treatment with Permethrin has the benefits of rapid resolution of skin lesions and itching compared to oral Ivermectin.

Recommendations:
Following recommendations are made based on the study findings:

- This study consists of small number of patients & shorter durations; it emphasizes the fact that further evaluation of the role of oral Ivermectin and topical Permethrin in the treatment of scabies in larger number of patients with longer duration will provide better clarification.

- More follow up should be done to evaluate the better outcome of the patients.

- Longitudinal studies (Cohort study) with larger samples can evaluate the effective and long term outcome for the patients.

Limitation of the study:
In our country, over-the-counter drugs are available. Many patients had to be withdrawn from the study because they used over-the-counter drugs in case of Ivermectin group for immediate relief.

References:


